Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Pimozide

Drug and asset intelligence for Pimozide with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Novitium Pharma →

Recent signals(2)

StrategyJuly 26, 2026

FDA Approves Pimozide Application ANDA219897 from Novitium Pharma

The FDA has approved the application ANDA219897 for Pimozide submitted by Novitium Pharma.

StrategyJune 9, 2026

FDA Grants Approval for Pimozide ANDA219897 by Novitium Pharma

The FDA has granted approval for ANDA219897, a generic formulation of Pimozide submitted by Novitium Pharma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Pimozide

June 9, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antipsychotic →
Neurology →
Neurology · Antipsychotic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.